Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 109 Show results per page	View Search Criteria \| Help With Results


1.		XeNA Study - A Study of Xeloda (Capecitabine) in Patients With Invasive Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV				Treatment				Closed				18 and over				Pharmaceutical / Industry				ML18530 NCT00127933

Last Modified: 1/15/2008 First Published: 8/1/2001


2.		Phase II/III Randomized Study of Anastrozole With or Without Trastuzumab (Herceptin) in Postmenopausal Women With Hormone-Receptor Positive HER2-Overexpressing Metastatic Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				18 and over				Pharmaceutical / Industry				ROCHE-BO16216 CWRU-030118, GENENTECH-H2223g, ROCHE-1100, ROCHE-B016216F, NCT00022672

Last Modified: 9/1/1995


3.		Phase III Randomized Study of Chemotherapy with vs without Monoclonal Antibody HER2 in Women with Metastatic Breast Cancer Overexpressing HER2/neu and Previously Untreated with Cytotoxic Chemotherapy (Summary Last Modified 09/95)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 to 75				Pharmaceutical / Industry				GENENTECH-HO648G NCI-V95-0714

Last Modified: 7/1/1998


4.		Phase III Randomized, Single-Blind Study of Monoclonal Antibody HER2 in Chemotherapy-Naive Metastatic Breast Cancer That Overexpresses HER2/neu (Summary Last Modified 07/98)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over				Pharmaceutical / Industry				UCLA-HSPC-9510492 NCI-V96-0947

Last Modified: 12/22/2008 First Published: 9/1/1998


5.		Phase III Randomized Study of Paclitaxel Via One-Hour Infusion Every Week Versus Three-Hour Infusion Every 3 Weeks With or Without Trastuzumab (Herceptin®) in Women With Inoperable, Recurrent, or Metastatic Breast Cancer With or Without Overexpression of HER2/neu

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over				NCI				CLB-9840 NCT00003440, CALGB-9840

Last Modified: 9/23/2008 First Published: 10/1/1999


6.		Phase III Randomized Study of Doxorubicin and Cyclophosphamide Followed By Paclitaxel With or Without Trastuzumab (Herceptin®) in Women With Node-Positive Breast Cancer That Overexpresses HER2

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				Not specified				NCI				NSABP-B-31 NCT00004067

Last Modified: 1/6/2009 First Published: 7/1/2000


7.		Phase III Randomized Study of Doxorubicin Plus Cyclophosphamide Followed By Paclitaxel With or Without Trastuzumab (Herceptin®) in Women With HER-2-Overexpressing Node-Positive or High-Risk Node-Negative Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over				NCI				NCCTG-N9831 CALGB-49909, ECOG-N9831, SWOG-N9831, GUMC-00224, N9831, NCT00005970, CAN-NCIC-MA28, MA28

Last Modified: 8/2/2007 First Published: 5/1/2001


8.		Phase III Randomized Study of Doxorubicin and Cyclophosphamide With or Without Dexrazoxane, Followed By Paclitaxel With or Without Trastuzumab (Herceptin), Followed By Surgery and Radiotherapy With or Without Trastuzumab in Women With HER-2+ Stage IIIA or IIIB or Regional Stage IV Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Supportive care, Treatment				Completed				18 and over				NCI				CLB-49808 NCT00016276, CALGB-49808

Last Modified: 9/23/2008 First Published: 7/1/2001


9.		Phase III Randomized Study of Adjuvant Doxorubicin, Cyclophosphamide, and Docetaxel With or Without Trastuzumab (Herceptin) Versus Trastuzumab, Docetaxel, and Either Carboplatin or Cisplatin in Women Who Have Undergone Surgery For HER2-neu-Expressing Node-Positive or High-Risk Node-Negative Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 to 70				NCI, Pharmaceutical / Industry				AVENTIS-TAX-GMA-302 UCLA-0102006, BCIRG-006, UAB-0106, UAB-F010326012, NCI-G01-1978, NCT00021255

Last Modified: 9/23/2008 First Published: 9/1/2002


10.		Phase III Randomized Study of Trastuzumab (Herceptin®) Versus No Herceptin in Women With HER-2 Positive Primary Breast Cancer Who Have Completed Adjuvant Chemotherapy

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over				Other, Pharmaceutical / Industry				BIG-01-01 EU-20216, ROCHE-B016348E, ROCHE-B016348C, EORTC-10011, CAN-NCIC-MA24, IBCSG-28-02, NCT00045032, MA24

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute